Baker Bros. Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Baker Bros. Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,455,202	Closed	-$55.9M	–	114
2023 Q2	$55.9M	Hold	1,455,202	–	–	0.32%	22
2023 Q1	$33.7M	Sell	1,455,202 -1,078,900	-43%	-$25.7M	0.18%	29
2022 Q4	$66.4M	Hold	2,534,102	–	–	0.4%	18
2022 Q3	$49.8M	Hold	2,534,102	–	–	0.33%	27
2022 Q2	$44.3M	Buy	2,534,102 +200,000	+9%	+$3.14M	0.25%	28
2022 Q1	$38.2M	Hold	2,334,102	–	–	0.22%	36
2021 Q4	$38.1M	Buy	2,334,102 +431,033	+23%	+$6.14M	0.19%	41
2021 Q3	$24.3M	Buy	1,903,069 +822,676	+76%	+$10.8M	0.11%	57
2021 Q2	$15.3M	Buy	1,080,393 +331,700	+44%	+$5.31M	0.07%	68
2021 Q1	$11.6M	Hold	748,693	–	–	0.05%	72
2020 Q4	$11.9M	Buy	+748,693	New	+$11.3M	0.04%	69

Baker Bros. Advisors's KDNY Position: Q3 2023 in Review

Baker Bros. Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,455,202 shares — an estimated $55.9M sold.

Baker Bros. Advisors first reported a position in KDNY in Q4 2020 and held it in 11 quarters. The position peaked at $66.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Baker Bros. Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Baker Bros. Advisors sold 1,455,202 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $55.9M.
Baker Bros. Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Baker Bros. Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $66.4M in Q4 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.